“Overall, my take is that even with an intense PSMA-targeted radionuclide regimen, I think the chance of a response… at least by PSA, is higher with stronger baseline PSMA imaging,” says Scott T. Tagawa, MD, MS, FACP.
In this video, Scott T. Tagawa, MD, MS, FACP, discusses the background and findings of the study, “PSMA imaging and outcome following dose-intense PSMA-targeted radionuclide therapy in men with PSMA-unselected, pre-treated, metastatic castration-resistant prostate cancer,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Tagawa is an associate professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital.
UGN-102 reaches nearly 80% complete response rate in low-grade intermediate-risk NMIBC
November 30th 2023Primary chemoablative therapy with the mitomycin-containing reverse thermal gel UGN-102 induced complete responses in nearly 4 out of 5 patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.